FEB 27, 2019 12:00 PM PST

Evaluating Biomarkers for Response to Neoadjuvant Immune Checkpoint Blockade in Melanoma

Presented at: Drug Discovery 2019
Sponsored by: NanoString Technologies
Speaker

Abstract

Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy, or immunotherapy. Previous preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade may lead to increased survival compared to adjuvant treatment1. This webinar will cover recent data from parallel but independent clinical trials explored the efficacy of anti-PD-1 and/or anti-CLTA4 combination immunotherapy plus surgery in patients with early stage melanoma2,3. 

In each study, safety of the treatment regimen and evidence of immune activity in response to treatment was evaluated. In addition to standard H&E and immunohistochemistry (IHC) staining before and after treatment each study also employed NanoString’s GeoMx™ Digital Spatial Profiler to perform high-plex proteomic analysis with spatial resolution. GeoMx DSP enabled the discovery of markers of antigen presentation (β2M) and T cells (CD3) present on pretreatment tumor biopsies that correlated with clinical efficacy in each study. Additionally, the responses to therapy in each study were strong enough to merit larger trials and continued investigation of the most effective immunotherapy strategy.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Learning Objectives: 

1. Gain an appreciation for how multiplexed spatial profiling via GeoMx can aid in tumor characterization
2. Understand how GeoMx profiling was used in the 2 studies presented to identify biomarkers of response to immunotherapy and complement other molecular profiling strategies


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
FEB 27, 2019 12:00 PM PST

Evaluating Biomarkers for Response to Neoadjuvant Immune Checkpoint Blockade in Melanoma

Presented at: Drug Discovery 2019
Sponsored by: NanoString Technologies


Show Resources
Loading Comments...
Show Resources